The Latest
-
Amwell mulls divestitures
The company is considering selling assets that could be more easily separated from the rest of the business without creating challenges for customers, executives said on a third quarter earnings call.
-
Prospect clashes with Rhode Island regulators over plans to close two hospitals
Prospect Medical Holdings is seeking approval from a bankruptcy court to close its hospitals in Rhode Island. Regulators and the new buyer say Prospect needs to follow through with a deal to sell them.
-
UnitedHealthcare pays Optum doctors more than other doctors: study
Researchers said the results suggest UnitedHealth may be sidestepping government rules meant to keep a lid on exorbitant payer profits. UnitedHealth said the study was “flat-out wrong.”
-
Legislators object to proposed CMS payment changes for diabetes tech
In a letter to CMS Administrator Dr. Mehmet Oz, diabetes caucus leaders raised concerns that the agency’s proposals will reduce access to glucose monitors and insulin pumps.
-
Health system execs are prioritizing AI, digital tech to overhaul care delivery: survey
Leaders are worried some of the sector’s persistent challenges — like finance pressures and worker burnout — could worsen over the next five years without significant changes, according to a survey by Chartis.
-
Federal ACA enrollment kicks off without action on subsidies
Millions of Americans are facing steep price hikes for Affordable Care Act coverage while Congress dithers over the issue. Experts say there’s not as much time to act as legislators may believe.
-
Health groups urge passage of bill to ease Medicare pay cuts for tests
More than 30 organizations, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests.
-
Medicare finalizes controversial cut to specialty care next year
The CMS finalized the Medicare physician fee schedule for 2026 on Friday, one day before the statutory deadline. It includes an overall payment hike and a few policies that are deeply unpopular with specialists.
Updated Nov. 4, 2025 -
CHS inks deal to sell stake in Tennessee hospital to VUMC
The $600 million deal was foreshadowed during the company’s third quarter earnings call this month, when CEO Kevin Hammons said more hospital sales were in the works.
-
HRSA approves 340B rebate models to hospitals’ chagrin
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.
-
Few health systems report significant ROI from virtual care: survey
Fewer than 30% of health system leaders said they earned a significant return on investment from virtual care offerings, according to the report by Sage Growth Partners.
-
Opinion
New CBO report confirms 340B’s ballooning costs. Congress must act.
Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.
-
Cigna’s 2026 pharmacy profits could be dampened by transition to rebate-free model
Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and discounted contracts for some big clients could lower Express Scripts’ profitability, executives said.
-
Summa Health CEO to step down at end of 2025
Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of Summa.
-
Teladoc expands insurance coverage at mental health unit BetterHelp
Executives expect insurance coverage availability will be “largely national” by the end of 2026. The initiative is important for Teladoc to turn around financial performance for the segment, which has seen earnings and revenue decline.
-
CVS hikes 2025 guidance despite goodwill impairment charge on healthcare delivery
The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 billion charge linked primarily to decelerating clinic growth at Oak Street Health.
-
Tenet pledges more money for high-acuity growth in 2025
The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for services.
-
Centene posts $6.6B loss on massive value writedown
The goodwill impairment charge is meant to realign Centene’s value on its own books with its value in the market, which has plummeted this year. Still, Centene upped its earnings outlook for 2025.
-
FDA, aiming to lower drug costs, moves to speed approval of biosimilars
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply.
-
UnitedHealth maps path back to Wall Street’s good graces
The healthcare giant beat Wall Street expectations in the third quarter and raised its 2025 earnings guidance, albeit modestly.
-
Voters blame insurers for medical debt: poll
More than 60% of respondents said insurance companies are most at fault for medical debt, compared with just 9% who blamed hospitals, according to a survey by nonprofit Undue Medical Debt.
-
UHS raises revenue guidance for 2025
The operator increased its outlook after posting earnings growth in the third quarter, aided by strong demand for services in its acute business and a newly approved Medicaid state supplemental payment program.
-
National payers OK on price transparency compliance: Turquoise Health
The company has started to score insurers on their success in making rate data available online. Large payers tend to do better than their smaller peers.
-
Deep Dive // HLTH25
Health systems are racing to adopt AI. But can they prove its value?
Measuring financial returns from AI can be challenging, experts said at the HLTH conference last week. But other metrics, like provider and patient satisfaction, are important too — and also impact providers’ bottom lines.
-
Cigna’s Express Scripts to transition away from rebate drug model
The massive PBM also said it will move to a cost-plus reimbursement model for in-network pharmacies. The moves come as the controversial drug middlemen attempt to lessen regulatory scrutiny.